Abstract
Background
Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue malignancy that typically presents with local invasion but rarely metastasizes. We examine clinicopathologic factors associated with disease-free survival (DFS) in patients with primary and recurrent DFSP and evaluate responses to multimodality therapy.
Materials and Methods
Patients treated for DFSP were identified in a prospectively maintained database. Clinicopathologic factors associated with DFS were analyzed using univariate and multivariate analysis.
Results
A total of 244 patients with DFSP were identified. Median follow-up was 50 months. A total of 14 patients had local recurrence (LR), and 2 patients had distant recurrence (DR), with a median time to recurrence of 35 months. At time of last follow-up, 70% and 47% of patients showed no evidence of disease (NED) in the primary (n = 197) and recurrent groups (n = 47), respectively. On univariate analysis, tumor location and depth were associated with DFS in the primary group, while margin status (R1 vs. R0) was associated with DFS in the LR group. On multivariate analysis, only depth (primary group) and margin status (LR group), remained significant. Also, 22 patients had therapy other than surgical resection: 14 radiotherapy, 4 tyrosine kinase inhibitor (TKI) only, 2 conventional chemotherapy only, and 2 chemotherapy plus TKI. Responses to other therapies were variable.
Conclusions
DFS after treatment for DFSP is strongly predicted by tumor depth in the primary setting and margin status in recurrent tumors. The treatment for DFSP in the primary or recurrent setting is excision with negative margins, resulting in low recurrence rates and infrequent metastatic spread. Multimodality treatment, especially TKI use, can be effective, but is not curative.
Similar content being viewed by others
References
Lemm D, Mugge LO, Mentzel T, Hoffken K. Current treatment options in Dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009;135:653–65.
Sundram UN. Review: Dermatofibrosarcoma protuberans: histologic approach and updated treatment recommendations. Clin Adv Hematol Oncol. 2009;7:406–8.
Gloster HM, Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:355–74; quiz 375–6.
Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in Dermatofibrosarcoma protuberans. Am J Surg Pathol. 1988;12:287–93.
Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Fibrosarcomatous (“high-grade”) Dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576–87.
Naeem R, Lux ML, Huang SF, Naber SP, Corson JM, Fletcher JA. Ring chromosomes in Dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol. 1995;147:1553–8.
Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in Dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15:95–8.
Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from Dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623–6.
McArthur G. Molecularly targeted treatment for Dermatofibrosarcoma protuberans. Semin Oncol. 2004;31:30–6.
McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol. 2006;18:341–6.
McPeak CJ, Cruz T, Nicastri AD. Dermatofibrosarcoma protuberans: an analysis of 86 cases—five with metastasis. Ann Surg. 1967;166:803–16.
Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711–20.
Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23:7669–75.
Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall WM. Radiotherapy in the treatment of Dermatofibrosarcoma protuberans. Am J Clin Oncol. 2005;28:537–9.
Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol. 2000;57:175–81.
DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK. Low recurrence rate after surgery for Dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100:1008–16.
Misset J, Kerob D, Porcher R, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: result of a multicentric phase II study on 25 patients. J Clin Oncol. 2007;25:10032.
McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced Dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866–73.
Popov P, Bohling T, Asko-Seljavaara S, Tukiainen E. Microscopic margins and results of surgery for Dermatofibrosarcoma protuberans. Plast Reconstr Surg. 2007;119:1779–84.
Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for Dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30:341–5.
Khatri VP, Galante JM, Bold RJ, Schneider PD, Ramsamooj R, Goodnight JE, Jr. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol. 2003;10:1118–22.
Koh CK, Ko CB, Bury HP, Wyatt EH. Dermatofibrosarcoma protuberans. Int J Dermatol. 1995;34:256–60.
Garcia C, Viehman G, Hitchcock M, Clark RE. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability. Dermatol Surg. 1996;22:177–9.
Massey RA, Tok J, Strippoli BA, Szabolcs MJ, Silvers DN, Eliezri YD. A comparison of frozen and paraffin sections in Dermatofibrosarcoma protuberans. Dermatol Surg. 1998;24:995–8.
Gloster HM, Jr., Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:82–7.
Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of Dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600–13.
Mendoza CB Jr., Gerwig WH, Jr., Watne AL. Dermatofibrosarcoma protuberans with metastases treated with methotrexate. Am J Surg. 1970;120:119–21.
Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic Dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20:3586–91.
Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717–25.
Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced Dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–9.
McArthur GA. Molecular targeting of Dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw. 2007;5:557–62.
Clinicaltrials.gov (2010). Search for clinical trials for patients with Dermatofibrosarcoma protuberans (DFSP). http://www.clinicaltrials.gov/ct2/results?term=dfsp. Accessed 1 March 2010.
Acknowledgment
Supported by Grants from the National Cancer Institute CA47179 (LXQ, RGM, SS, MFB), CA148260 (RGM), the National Cancer Institute-American Society of Clinical Oncology Cancer Foundation Clinical Investigator Team Leadership Supplemental Award (RGM), the Cycle for Survival (RGM), and the Shuman Fund for GIST Research (RGM).
Disclosure
RGM serves on an advisory board for Novartis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fields, R.C., Hameed, M., Qin, LX. et al. Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Ann Surg Oncol 18, 328–336 (2011). https://doi.org/10.1245/s10434-010-1316-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-010-1316-5